financetom
Business
financetom
/
Business
/
Prada gets exclusive four week access to Versace financial data, source says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Prada gets exclusive four week access to Versace financial data, source says
Feb 20, 2025 10:29 AM

(refiles to fix day in first paragraph)

MILAN, Feb 20 (Reuters) - Italian luxury group Prada

has been given access, ahead of any other potential

suitors, to the financial data of smaller rival Versace which

owner Capri Holdings ( CPRI ) has put up for sale, a source

close to the matter said on Thursday.

Prada has four weeks to conduct its assessment, the source

said, as it weighs an acquisition that would mark a significant

shift in strategy. No decision on whether to actually pursue the

deal has yet been taken at this stage, the source added.

Capri Holdingss is working with Barclays ( JJCTF ) to explore a

sale of its Versace and Jimmy Choo brands, sources told Reuters

this year.

Prada and Barclays ( JJCTF ) declined to comment. Capri Holdings ( CPRI ) was

not immediately available for a comment.

Prada last completed acquisitions of other brands in the

late 1990s and has been focusing on internal growth since then,

defying expectations it could aspire to create a larger Italian

fashion hub.

The acquisition of Versace would allow Prada to target a

different customer group, with tastes far from Prada's trademark

minimalism.

But the Hong-Kong listed group would also have to deal with

a challenging turnaround of the Medusa-logo brand, industry

sources said.

Versace reported a 15% decline in revenues in the third

quarter ending on December 28 and the operating loss increased

to $21 million in the period, from $14 million a year earlier.

Capri Holdings ( CPRI ) expects Versace's revenues to drop to $810

million in the 2025 fiscal year and the operating margin to

break even in the following fiscal year, according to long term

financial targets published on Wednesday.

The brand's performance and the sector's bleak outlook could

make it hard to set a price, complicating negotiations,

according to industry sources, who said a turnaround would

require investment.

Capri Holdings ( CPRI ), formerly known as Michael Kors, bought

Italian luxury brand Versace in 2018, for 1.83 billion euros

including debt.

The four week exclusivity deal was first reported on

Thursday by Italian daily Il Sole 24.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Phunware Proposes $120 Million Common Stock Offering
Phunware Proposes $120 Million Common Stock Offering
Jun 4, 2024
05:53 PM EDT, 06/04/2024 (MT Newswires) -- Phunware ( PHUN ) said late Tuesday that it is seeking regulatory clearance to sell up to $120 million of its shares through an at-the-market offering. The company, which has filed a prospectus supplement to its existing shelf registration statement, said that no additional capacity is being added to the registration statement as...
Zevra Therapeutics Files $350 Million Mixed-Shelf; Shares Fall After Hours
Zevra Therapeutics Files $350 Million Mixed-Shelf; Shares Fall After Hours
Jun 4, 2024
05:53 PM EDT, 06/04/2024 (MT Newswires) -- Zevra Therapeutics ( ZVRA ) filed a shelf registration statement with the US Securities and Exchange Commission Tuesday covering the potential sale of up to $350 million of its securities from time to time in one or more offerings. The statement covers the company's common and preferred shares, debt securities and warrants, according...
Vision Sensing Acquisition Files Form 10-Q to Regain Nasdaq Compliance
Vision Sensing Acquisition Files Form 10-Q to Regain Nasdaq Compliance
Jun 4, 2024
05:56 PM EDT, 06/04/2024 (MT Newswires) -- Vision Sensing Acquisition ( VSAC ) filed Tuesday its form 10-Q for the period ended March 31, five days after receiving a noncompliance notice from Nasdaq for the delay. The company said it was given a 60-day period to regain compliance. ...
Cellectis Gets Orphan Drug Label From European Commission For Acute Lymphoblastic Leukemia
Cellectis Gets Orphan Drug Label From European Commission For Acute Lymphoblastic Leukemia
Jun 4, 2024
05:52 PM EDT, 06/04/2024 (MT Newswires) -- Cellectis ( CLLS ) said late Tuesday that the European Commission has granted an orphan drug designation to the company's product candidate UCART22 to treat acute lymphoblastic leukemia. The European Medicines Agency considered the significant benefit of UCART22 has been demonstrated based on the preliminary data generated with UCART22 in heavily pretreated patients...
Copyright 2023-2026 - www.financetom.com All Rights Reserved